Advertisement

Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

Pharmacokinetic studies of flumecinol in man and dog

  • 7 Accesses

  • 5 Citations

Summary

The pharmacokinetics of flumecinol (Zixoryn®) a new hepatic enzyme inducer has been studied in four beagle dogs and six healthy volunteers. The beagle dogs and the volunteers received the drug orally in a dose of 40 mg/kg of body weight and of 100 mg single dose respectively.

Flumecinol was extracted from plasma with diethyl ether and analysed by gas-liquid chromatography using a flame ionisation detector (FID). The pharmacokinetic parameters of flumecinol were determined by computer evaluation of the plasma concentration-time curves. The peak plasma concentrations were found to be 3.3 and 2.1 hours in dogs and humans, respectively. Flumecinol is eliminated from the plasma of dogs and humans with half-lives of 38.95 and 17.16 hours, corresponding to a clearance of 53.2 litres/hour and 94.0 litres/hour, respectively.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Tóth E., Szeberényi Sz., Pálosi E., Szporny L., Görög S. and Mészáros Cs. (1977): Brit. Pat. Spec. N0 1478185.

  2. 2.

    Szeberényi Sz., Pálosi É. and Szporny L. (1978): Effects of 3-trifluoromethyl-α-ethylbenzhydrol (RGH- 3332), a new enzyme inducer, on the microsomal drug metabolism. Part I., Arzneim. Forsch. (Drug Res.),28. 663–668.

  3. 3.

    Pálosi É., Szeberényi Sz. and Szporny L. (1978): Effects of 3-trifluoromethyl-a-ethylbenzhydrol (RGH- 3332), a new enzyme inducer on the central-nervous system of rats. Part II., Arzneim. Forsch. (Drug Res.),28. 669–672.

  4. 4.

    Váradi A. (1978): 3-trifluoromethyl-α-ethylbenzhydrol (RGH-3332) liver enzyme induction and D-glucaric acid excretion. Arzneim. Forsch. (Drug Res.),28, 678–679.

  5. 5.

    Gachályi B., Káldor A. and Szeberényi Sz. (1978): m-trifluoromethyl-α-ethylbenzhydrol: A new enzyme inducer. Europ. J. Clin. Pharmac,13, 299–302.

  6. 6.

    Roots I., Saalfrank K. and Hildebrant A.G. (1975): in Cytochromes P450 and b5, Ed. Cooper D.Y., et al. 485–502. Plenum Press, New York-London.

  7. 7.

    Trolle D. (1968): Decrease of total serumbilirubin concentration in newborn infants after phenobarbitone treatment. The Lancet,28. 705–708.

  8. 8.

    Klebovich I. and Vereczkey L. (1980): A gas chromatographic method for the determination of flumecinol in biological fluids. J. Chromatog. Biomed. Appl.221. 404–407.

  9. 9.

    Gibaldi, M. and Perrier D. (1975): Drug and Pharmaceutical Sciences Vol. I. Pharmacokinetics, Ed. by Swarbrick J., Marcell Dekker Inc., New-York.

  10. 10.

    Wagner J.G. (1971): Biopharmaceutics and relevant pharmacokinetics. Drug Inteligence Publ. Hamilton, III.

  11. II.

    Kellerman G. and Luyten-Kellerman M. (1977): Phenobarbital-induced drug metabolism on man. Toxicol. Appl. Pharmacol.,39. 97–104.

  12. 12.

    Pagliaro LA. and Benet L.Z. (1975): Pharmacokinetic data Critical compilation of terminal half-lives, percent excreted unchanged, and changes of half-life in renal and hepatic dysfunction for studies in humans with references. J. Pharmacol. Biopharm.3. 333–383.

Download references

Author information

Correspondence to I. Klebovich.

Additional information

A part of this paper was presented at the 3rd Congress

A part of this paper was presented at the 3rd Congress

A part of this paper was presented at the 3rd Congress

A part of this paper was presented at the 3rd Congress

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Klebovich, I., Vereczkey, L., Kerpel-Fronius, S. et al. Pharmacokinetic studies of flumecinol in man and dog. European Journal of Drug Metabolism and Pharmacokinetics 7, 99–104 (1982). https://doi.org/10.1007/BF03188725

Download citation

Key words

  • Flumecinol
  • enzyme inducer
  • pharmacokinetics
  • man
  • dog